Clinical Trial Update: A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC [Phase 2]

View source ↗

Summary

This Phase 2a open-label study evaluated MORF-057 for efficacy and safety in adults with ulcerative colitis. The trial is completed and results have been posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• MORF 057

Snippet

Sponsor: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | Conditions: Inflammatory Bowel Diseases, Colitis, Ulcerative | Phase 2 | Status: COMPLETED | Results posted: 2024-11-26